Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Benzylamphetamine SCHEMBL2798189 | 1.00 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| N-Benzylamphetamine SCHEMBL2795222 | 1.00 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| N-Benzylamphetamine SCHEMBL8085021 | 0.98 | SIGMAR1 (0.96) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL606189 | 0.92 | SIGMAR1 (0.85) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL608555 | 0.91 | SIGMAR1 (0.82) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL8092729 | 0.91 | SIGMAR1 (0.82) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL24997843 | 0.89 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL10005270 | 0.89 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL3235181 | 0.89 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL8091283 | 0.89 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | claimed |
| EP-1017358-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1017358-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-07-12 | — | — | EP | claimed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | claimed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-110668952-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-1038522-A2 | Anticonvulsant enantiomeric amino acid derivatives | Research Corporation Technologies, Inc (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0938467-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | disclosed |
| US-5891696-A | CAN BE STORED AT A TEMPERATURE LESS THAN 8.DEGREE. C. FOR AT LEAST TWO WEEKS AND IS ABLE TO OXIDIZE A DRUG AFTER STORAGE | PANVERA CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0888289-A1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | Research Corporation Technologies, Inc (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5773475-A | DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997033861-A1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SIGMAR1 78/4885LMNA 4850/4885POLB 3555/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | SIGMAR1 1213/4885LMNA 4701/4885POLB 4724/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SIGMAR1 67/4885LMNA 4876/4885POLB 3828/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SIGMAR1 67/4885LMNA 4876/4885POLB 3828/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SIGMAR1 80/4885LMNA 4869/4885POLB 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.